Summit Therapeutics SMMT Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $20.04M.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total debt?
- Summit Therapeutics (SMMT) reported total debt of $20.04M in Q1 2026.
- How has Summit Therapeutics's total debt changed year-over-year?
- Summit Therapeutics's total debt increased by 210.7% year-over-year, from $6.45M to $20.04M.
- What is the long-term trend for Summit Therapeutics's total debt?
- Over 5 years (2020 to 2025), Summit Therapeutics's total debt has grown at a 114.0% compound annual growth rate (CAGR), from $465K to $20.89M.
- What does total debt mean?
- The total amount of money the company owes to lenders and creditors through loans, bonds, and lease obligations.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten financial risk for a pre-commercial company. A decrease indicates deleveraging or the repayment of obligations, potentially improving the balance sheet's solvency profile.
- How does total debt compare across companies?
- Biopharmaceutical peers in the clinical development stage often carry varying levels of debt depending on their access to capital markets and strategic financing decisions, with many early-stage firms prioritizing equity financing over debt to avoid interest burdens.